Want to see SNTI full AI Analyst Report?
SNTI Stock Chart & Stats
$0.40
>-$0.01(-0.97%)
At close: 4:00 PM EDT
$0.40
>-$0.01(-0.97%)
Day’s Range― - ―
52-Week Range$0.33 - $2.88
Previous CloseN/A
Volume63.62K
Average Volume (3M)299.89K
Market Cap
$13.40M
Enterprise Value$40.95
Total Cash (Recent Filing)$6.46M
Total Debt (Recent Filing)$20.23M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.77
Shares Outstanding31,144,754
10 Day Avg. Volume584,382
30 Day Avg. Volume299,887
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)41.84
Price to Sales (P/S)10628.51
P/FCF Ratio-5.36
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.04
Revenue Forecast (FY)$38.67K
Bulls Say, Bears Say
Bulls Say
Synthetic Biology PlatformSenti's synthetic-biology and gene-circuit capabilities provide a differentiated platform for designing more controlled cell therapies. If validated clinically, these engineering features could support multiple oncology programs and create partnering opportunities beyond a single product.
Collaboration-Based Revenue PotentialA collaboration and licensing model can help fund development through partner payments and research support while preserving potential milestone and royalty upside. This gives the platform several possible commercialization paths before internally funded product sales become available.
Debt And Burn DirectionLower absolute debt and a modest reduction in operating cash burn are constructive directional changes. They may modestly extend financial flexibility and reduce near-term funding pressure, although the company remains dependent on financing or partnerships.
Bears Say
Minimal Revenue And Deep LossesThe company has almost no current revenue base relative to its operating expenses, leaving little internal funding capacity. Persistent large losses indicate that clinical development remains dependent on external capital, partnerships, or future regulatory success.
Persistent Cash ConsumptionSustained negative operating and free cash flow means the business continues consuming substantial liquidity to fund operations. Without materially higher revenue or lower spending, ongoing development will likely require additional financing and could create dilution or funding risk.
Negative Equity And Shrinking Asset BaseNegative equity and a sharply smaller asset base signal weakened financial resilience and limited balance-sheet flexibility. Even with lower debt, the depleted capital base reduces the company's ability to absorb setbacks or fund lengthy clinical programs without new capital.
Senti Biosciences News
SNTI FAQ
What was Senti Biosciences, Inc.’s price range in the past 12 months?
Senti Biosciences, Inc. lowest stock price was $0.33 and its highest was $2.88 in the past 12 months.
What is Senti Biosciences, Inc.’s market cap?
Senti Biosciences, Inc.’s market cap is $13.40M.
When is Senti Biosciences, Inc.’s upcoming earnings report date?
Senti Biosciences, Inc.’s upcoming earnings report date is Nov 12, 2026 which is in 84 days.
How were Senti Biosciences, Inc.’s earnings last quarter?
Currently, no data Available
Is Senti Biosciences, Inc. overvalued?
According to Wall Street analysts Senti Biosciences, Inc.’s price is currently Overvalued.
Does Senti Biosciences, Inc. pay dividends?
Senti Biosciences, Inc. does not currently pay dividends.
What is Senti Biosciences, Inc.’s EPS estimate?
Senti Biosciences, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Senti Biosciences, Inc. have?
Senti Biosciences, Inc. has 31,144,754 shares outstanding.
What happened to Senti Biosciences, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Senti Biosciences, Inc.?
Currently, no hedge funds are holding shares in SNTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Senti Biosciences, Inc.
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogram cells. This allows the modified cells to interpret biological cues, make precise decisions, and react appropriately within their specific cellular surroundings. Their proprietary synthetic biology platform leverages readily available, "off-the-shelf" chimeric antigen receptor natural killer (CAR-NK) cells. This innovative approach is specifically designed to tackle formidable liquid and solid tumor cancers. Among their leading therapeutic candidates is SENTI-202. This "Logic Gated OR+NOT" off-the-shelf CAR-NK cell therapy is engineered to selectively identify and destroy acute myeloid leukemia (AML) cells, critically leaving healthy bone marrow unharmed. Another key program, SENTI-301, is a multi-armed, ready-to-use CAR-NK cell therapy being developed for the treatment of hepatocellular carcinoma (HCC). Additionally, SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy, aims to precisely eliminate colorectal cancer (CRC) cells without damaging the body's healthy tissues. Established in 2016, Senti Biosciences maintains its headquarters in South San Francisco, California.
Technical Analysis
Ownership Overview
2.63% Insiders
0.46% Mutual Funds
0.11% Other Institutional Investors
95.06% Public Companies and
Individual Investors